ApoB: Why ‘Normal’ Cholesterol Can Still Hide Risk
Why ‘normal’ cholesterol can still hide risk
Apolipoprotein B (ApoB) is a protein that sits on the surface of every cholesterol-carrying particle able to lodge in an artery wall: LDL, VLDL, IDL and lipoprotein(a). Each of these particles carries exactly one ApoB molecule, so an ApoB blood test counts the total number of artery-damaging particles in your circulation, rather than estimating the amount of cholesterol they happen to be carrying.[1]
Atherosclerosis is driven by particles, not by cholesterol in the abstract. One particle can carry a little cholesterol or a lot; what pushes into the artery wall and starts a plaque is the particle itself. A standard test reports LDL cholesterol (LDL-C), which is the cargo. ApoB reports how many delivery vehicles are on the road. When those two measures disagree, the particle count tends to be the more reliable guide to risk.[2]
This helps explain why some people with a “normal” LDL cholesterol still have heart attacks, and why others carry more risk than their reading suggests. Large 2022 and 2024 analyses found that ApoB captures cardiovascular risk more completely than LDL-C or non-HDL cholesterol, and that once ApoB is known, the traditional numbers add little.[3]
A standard lipid panel is a reasonable starting point, but it can understate or overstate risk in the people who most need an accurate number: those with insulin resistance, high triglycerides, or a family history of early heart disease. Measuring ApoB, a low-cost and widely available blood test, turns an estimate into a direct count.
What ApoB actually counts
Every lipoprotein that can drive atherosclerosis carries a single apolipoprotein B molecule on its surface. That includes low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) and lipoprotein(a). Because the ratio is fixed at one ApoB per particle, a blood ApoB concentration is a direct headcount of the particles capable of entering an artery wall.[1]
Cholesterol itself is not the villain. It is an essential building block for cell membranes, hormones and bile. The problem begins when too many ApoB-containing particles cross the inner lining of an artery, become trapped, and trigger the inflammatory response that builds plaque over decades. The number of particles crossing that lining is what sets the pace, and that number is what ApoB reports.[6]
A standard lipid panel does not count particles. It estimates how much cholesterol is packed inside your LDL particles and reports that as LDL-C. For most people this tracks reasonably well with particle number. For a large minority it does not, and that gap is where risk hides.
Why a ‘normal’ reading can mislead you
Two people can have an identical LDL cholesterol of, say, a comfortable-looking number, yet carry very different numbers of particles. The reason is that particles are not all the same size. Someone with insulin resistance or metabolic syndrome tends to make smaller, cholesterol-depleted LDL particles. To carry the same total cholesterol, they need more particles, so their ApoB, and their risk, runs higher than their LDL-C implies.[7]
This mismatch is common rather than rare. An analysis of UK Biobank participants found that around 18 percent had discordant ApoB and LDL-C, meaning one measure sat in a reassuring range while the other flagged concern.[4] High triglycerides, type 2 diabetes and a lower HDL all widen the gap, which is exactly the metabolic pattern we see often in clinic.
The practical consequence is simple. If you have been told your cholesterol is “fine” but you carry central weight, a raised fasting glucose, or a strong family history of early heart disease, a normal LDL-C alone may not be the reassurance it appears to be.
LDL-C, non-HDL-C and ApoB, side by side
Three ways of reading the same blood, and what each one is really telling you.
| Marker | What it measures | Main limitation |
|---|---|---|
| LDL-C | Cholesterol carried inside LDL particles, often calculated rather than measured | Can read “normal” while particle number is high, especially with high triglycerides or insulin resistance |
| Non-HDL-C | Cholesterol in all atherogenic particles (total minus HDL) | Closer to particle number than LDL-C, but still estimates cholesterol content, not particle count |
| ApoB | A direct count of all atherogenic particles, one ApoB per particle | Not yet ordered routinely by every clinician, though it is inexpensive and standardised |
When LDL-C, non-HDL-C and ApoB all agree, any of them works. When they disagree, major guidelines increasingly treat ApoB as the more accurate marker of risk.[8]
When ApoB and cholesterol disagree
The strongest evidence for using ApoB comes from studies that pit the markers against each other in the same people. A 2022 analysis in JAMA Cardiology of more than 389,000 adults found that ApoB captured the risk of heart attack associated with LDL particles, and that once ApoB was accounted for, LDL-C and triglycerides added essentially nothing further. In their words, ApoB behaved as the primary driver.[1]
A 2024 Journal of the American College of Cardiology study extended this to both sexes, reporting that an excess of ApoB-containing particles predicted cardiovascular events in women and men alike, and that the standard cholesterol numbers underestimated risk in people whose ApoB was high.[9] Genetic and long-term cohort work points the same way: the lifetime burden of ApoB particles, more than any single cholesterol reading, tracks with who develops arterial disease.[10]
This is why professional bodies have shifted. The 2019 European guidelines and the 2018 American cholesterol guideline both recognise ApoB as a more accurate measure of risk than LDL-C, particularly for people with high triglycerides, diabetes, obesity or a very low LDL-C.[11][12]
What ApoB testing looks like in practice
ApoB is a single blood test that most Australian pathology labs can run, and it does not usually require fasting. In a functional medicine consultation it is rarely read in isolation. We look at it alongside markers of insulin resistance such as fasting insulin and triglycerides, inflammatory markers, and lipoprotein(a), which is a largely inherited particle that a standard panel misses entirely.[2]
Reading these together turns a single number into a picture. A high ApoB alongside a raised fasting insulin and central weight points toward a metabolic, root-cause conversation about diet, muscle, sleep and movement, rather than a number treated in isolation. This layered reading is the same approach we take with complex chronic patterns. You can read more about how we work with metabolic health on the thyroid and metabolism page, and about the broader testing we use on the functional testing page.
None of this replaces your GP or cardiologist, and any decision about medication sits with them. The point of measuring ApoB is to make sure the number you are all working from reflects your real particle burden, not an estimate that may be flattering or falsely alarming.
Key Insights
Frequently Asked Questions
Is ApoB better than a standard cholesterol test?
For most people whose markers all agree, a standard panel is fine. ApoB becomes more useful when the numbers disagree, because it counts particles directly rather than estimating cholesterol content. Large 2022 and 2024 analyses found ApoB captured cardiovascular risk more completely than LDL-C or non-HDL cholesterol, and current European and American guidelines recognise it as a more accurate marker, especially for people with high triglycerides, diabetes or a very low LDL-C.
Can my ApoB be high if my cholesterol is normal?
Yes, and this is one of the main reasons the test is worth doing. If you make smaller, cholesterol-depleted particles, which is common with insulin resistance, metabolic syndrome or high triglycerides, you need more particles to carry the same cholesterol. Your LDL-C can look reassuring while your particle count, and your risk, runs higher. Around 18 percent of people in one large dataset had this kind of mismatch between ApoB and LDL-C.
Do I need to fast for an ApoB test?
Usually not. Unlike a calculated LDL-C, which can be thrown off by recent meals, ApoB is a direct measurement that is relatively stable whether or not you have eaten. Many labs will run it on a non-fasting sample. If your clinician is measuring several markers at once, they may still ask you to fast for the others, so follow the instructions you are given for the whole panel.
Should everyone get their ApoB tested?
Not everyone needs it, but it is especially worthwhile if you have insulin resistance, type 2 diabetes, high triglycerides, central weight, or a family history of early heart disease, since those are the situations where a standard cholesterol reading is most likely to mislead. It is also useful when a result seems out of step with how a person looks clinically. The test is inexpensive, so the barrier is usually awareness rather than cost.
Ready to find answers?
If your cholesterol has been called “fine” but something still doesn’t add up, a fuller look at your particle count and metabolic markers can tell you where you really stand.
References
- Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiology. 2022;7(3):250–256. PMID:34773460
- Glavinovic T, Thanassoulis G, de Graaf J, et al. Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk. Journal of the American Heart Association. 2022. PMC8540246
- Sniderman AD, Navar AM, Thanassoulis G. Apolipoprotein B in cardiovascular risk assessment. CMAJ. 2023;195(33):E1124–E1125. cmaj.ca/content/195/33/E1124
- Sniderman AD, et al. Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice. Circulation. 2024;150. doi:10.1161/CIRCULATIONAHA.124.068885
- Current opinions on the role of apolipoprotein B in the clinical management of cardiovascular risk. Future Cardiology. 2025. doi:10.1080/14796678.2025.2535184
- Apolipoprotein B in the Risk Assessment, Diagnosis, and Management of Cardiovascular Disease. PMC. 2025. PMC12674602
- Sniderman AD, Thanassoulis G, Glavinovic T, et al. The Lower the ApoB, the Better: Now, How Does ApoB Fit Into Clinical Practice? Circulation. 2022;146(23):1743–1745. doi:10.1161/CIRCULATIONAHA.122.061188
- Marston NA, et al. Apolipoprotein B and cardiovascular risk assessment. European Heart Journal. 2025;46(27):2702. eurheartj 46(27):2702
- Richardson TG, et al. Excess Apolipoprotein B and Cardiovascular Risk in Women and Men. Journal of the American College of Cardiology. 2024. doi:10.1016/j.jacc.2024.03.423
- Glavinovic T, Sniderman AD. Apolipoprotein B: The Rosetta Stone of Lipidology. PMC. 2021. PMC8540246
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Journal of the American College of Cardiology. 2019;73(24):e285–e350. doi:10.1016/j.jacc.2018.11.003
